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Abstract 
DLX6 belongs to the six-member family of DLX 
genes characterized by a homeobox related to that 
found in the insect Distal-less (Dll) gene. The six 
DLX genes are organized as three bigenic pairs 
with a tail-to-tail orientation (Zerucha et al., 2000), 
and located on chromosomes where HOX clusters 
are also found (DLX5/DLX6; 7q21.3, syntenic to 
the HOXA cluster), (DLX1/DLX2; 2q32 syntenic 
to the HOXD cluster) and (DLX3/DLX4; 17q21.33 
syntenic to the HOXB cluster). During embryonic 
development DLX genes are involved in the control 
of appendage and craniofacial morphogenesis and 
in the differentiation of reproductive organs; in the 
adult they play a role in bone homeostasis and in 
the maintenance of tissue integrity. 
Identity 
HGNC (Hugo): DLX6 
Location: 7q21.3 
Local order 
Forward strand of human chromosome 7, from 
96634860 to 96640352 - see Figure 1 below. DLX6 
forms a bigenic cluster with DLX5 at 7q21.31. 
DNA/RNA 
Description 
In contrast to DLX5, no intragenic mutations have 
been found for DLX6. It is considered that 
disruption of distant regulatory elements is most 
usually responsible for DLX5/DLX6-related 
disorders in human. Breakpoint analyses of 
genomic deletions and chromosomal 
rearrangements in the congenital split-hand/split-
foot malformation (SHFM type 1D, OMIM 
#220600), have shown that positional effect and 
disrupted regulatory elements controlling 
DLX5/DLX6 activity are involved in the 
pathogenesis of this developmental disorder (see 
further "dysmorphologies"). In-depth sequencing of 
the candidate regions has shown that the expression 
of DLX6 depends upon the activity of conserved 
regulatory elements shared with DLX5, and located 
both within the DLX5/DLX6 intergenic territory 
and outside of the locus (see Figure 1; Lango Allen 
et al., 2014). Furthermore these enhancers have 
been identified in all examined species - including 
in mouse where transgenic analyses have allowed 
the functional characterization of their tissue-
specificity. 
 
Figure 1. Genomic context of the human DLX5/DLX6 bigenic locus. 
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Figure 2. The four known human DLX6 transcripts. 
 
 
The status of parental imprinting of the 
DLX5/DLX6 locus has recently gained strong 
interest as these genes have been considered to be 
putative methylation targets of the methyl-CpG 
binding protein-2 (MECP2), and thus might be 
indirectly involved in the aetiology of the Rett 
syndrome, a severe X-linked neurodevelopmental 
disorder afflicting girls with MECP2 mutation (see 
further "Rett syndrome"). 
Transcription 
Transcription from DLX6 yields four splice 
variants, one transcript being untranslated (see 
Figure 2). The three coding ones range from 666 b 
to 2304 b (major isoform) due to alternative 
splicing sites throughout the precursor transcript. 
Furthermore, two antisense non-coding transcripts 
have been characterized - one of which, Evf2 
(Dlx6as/Dlx6os1; HNGC#37151), has been 
demonstrated to regulate transactivation from an 
intergenic enhancer of Dlx5/Dlx6 (Feng et al., 
2006; Berghoff et al., 2013). 
DLX6 sequence analysis of one sporadic SHFM 
patient (Ferro et al., 2001) has led to the discovery 
of a longer transcript endowing the N-terminus of 
DLX6 with an unusual dual poly-glutamine/poly- 
proline stretch, 11-20 CAG/CCG repeat long, 
which has been found to be conserved in mouse 
(Pfeffer et al., 2001; see further "trinucleotide 
repeats"). The functional consequences of these 
expansions upon DLX6 activity remain to be 
determined. 
Protein 
Description 
DLX6 is a 175 AA helix-turn-helix homeodomain 
transcription factor (19.7 kDa and pI 9.9). The 
homeodomain spans AA 49-108 across exons 2 and 
3 (see Figure 3). 
Function 
During mouse craniofacial morphogenesis, Dlx6 
acts as transactivator of the helix-loop-helix dHand 
gene through a regulatory element, [ATTA/TAAT], 
which does not bind other Dlx factors. Noticeably, 
this binding is a specifically endothelin-1 signaling-
dependent mechanism. Thus, despite sharing 
regulatory elements and subsequent expression 
patterns with Dlx5, the Dlx6 factor appears to be 
competent to exert selective roles depending upon 
specific cellular signalling contexts.  
 
Figure 3. Structure of the three DLX6 protein isoforms. Sequence below belongs to the longest isoform. Note the N-terminal 
series of poly-residue stretches. 
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Figure 4. NCBI/COBALT alignment of DLX homeoproteins. Note the disposition according to the DLX 1/4/6 versus DLX 2/3/5 
clades. Indicated by a yellow box is the ultraconserved Glutamine featured by most homeoproteins at position 50 of the 
homeodomain. 
 
As other DLX factors, DLX6 modulates target 
genes expression through a domain which is 
distinct from the DNA-binding homeodomain, and 
in association within transactivating complexes 
which include MSX.  
Composition biases in DLX6 include one poly-Gly 
and one-His stretches (see Figure 3). 
Of note, DLX6 encodes for one long isoform 
endowed with a contiguous series of residue 
stretches including glutamine, proline, alanine and 
histidine (see Figure 3). 
Homology 
With regards to other members of the DLX family, 
DLX6 belongs to the DLX1/4/6 clade based on 
sequence homology (see Figure 4). It shares a lack 
of N-terminal DLL-like domain specific to the other 
clade constituted by DLX2/3/5. The homeodomain 
remains close to all other DLX proteins. 
Implicated in 
Lung cancers 
Note 
Neoplastic processes often result from  
combinatorial activity of developmental genes 
(Abate-Shen, 2002).  
Dysregulated expression of homeobox-containing 
genes of the distal-less family, arranged as three 
bigenic pairs in mammals (DLX1/2, DLX3/4 and 
DLX5/6; Kraus and Lufkin, 2006), has been 
reported to correlate with distinct oncogenic 
mechanisms.  
DLX6 along with DLX5 is a direct MYC oncogene 
inducer, responsible for neoplastic initiation in 
many cancers, including lymphoma and lung 
cancers (Xu and Testa, 2009). 
Breast cancers and their bone 
metastases 
Note 
DLX6, together with DLX5, is upregulated in lung 
and bone metastatic cells derived from primary 
breast tumors in human - a pattern associated with 
tumour agressivity and thus, poor prognosis and 
increased relapses (Morini et al., 2010). 
Transcriptional profiling in search for prognosis 
markers has identified DLX6 as an upregulated 
candidate for high-grade astrocytomas (Phillips et 
al., 2006). 
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Dysmorphologies 
Note 
DLX6 is often regarded as a functional substitute of 
DLX5 and autonomous regulation as been seldom 
observed; one rare such situation being the 
Endothelin-1→Endothelin-Ra→Dlx6→Hand2 
signalling cascade which specifies lower jaw 
identity in the mouse embryo (Charité et al., 2001). 
As such, malformations described for DLX5 are 
commonly regarded as involving DLX6. In most 
mouse mutant models, severe phenotypes result 
from dual invalidation of Dlx5 and Dlx6. 
Malformative processes implying DLX6 will thus 
be simultaneously described on the DLX5 gene 
card.  
Split hand-foot malformation (SHFM) type 1 with 
sensory-neural hearing loss (SHFM1D; 
MIM:220600). This malformative syndrome affects 
hands and feet alike, resulting in moderate to severe 
median ray deficiency with syndactily. Among the 
described six non-syndromic SHFM loci, one spans 
the DLX5/DLX6 bigenic cluster (Scherer et al., 
1994; Crackower et al., 1996). Numerous reported 
mutations spare DLX5 or DLX6 open reading 
frames, suggesting it may rather be their common 
regulatory elements which is impacted (Robledo et 
al., 2002 ; Lo Iacono et al., 2008). However 
recently, two rare familial cases of SHFM1 have 
been demonstrated to result, with highest 
probability, from intragenic missense mutations of 
two critical glutamine residues in the third helix of 
the DLX5 homeodomain (Q178P reported in 
Shamseldin et al., 2012; and Q186H characterized 
in Wang et al., 2014). In the first case, a causal link 
between defective DLX5/DLX6 expression and the 
pathogenic mechanism impairing limb development 
remains to be elucidated. In the second case, the 
mutated DLX5 has been demonstrated to fail at 
transactivating its bona fide MYC target. Such an 
observation is not unexpected as the mutation 
affects Q50, the most conserved residue of all 
homeoproteins (see diagram), which numerous 
biochemical studies have demonstrated to be 
responsible for the specificity of the DNA 
recognition at the TAATT homeo-element (for 
review, Galliot et al., 1999).  
Other pathogenetic processes: on a further note, 
SHFM cases have often been reported to include 
hearing loss, a trait consistent with a developmental 
role demonstrated for Dlx5/Dlx6 during ear 
formation in mouse embryogenesis (Acampora et 
al., 1999; Merlo et al., 2002; Robledo and Lufkin, 
2006; Chatterjee et al., 2010; Frenz et al., 2010). 
Moreover, both genes are major targets of two 
regulator genes whose deficiencies are responsible 
for a related pathogenic condition, the auriculo-
condylar syndrome (ACS, Rieder et al., 2012). 
Anorectal malformation associated with SHFM has 
been reported in a family with a missense mutation 
in the P63 gene, a known direct upstream regulator 
of DLX5/DLX6 during morphogenesis (Su et al., 
2013). Whether DLX5/DLX6 expression is 
dysregulated in this condition, and whether this trait 
can be functionaly associated with the phenotype, 
remains to be elucidated. 
Trinucleotide repeats 
Note 
The first DLX6 exon harbours a trinucleotide repeat 
region of 11 to 20 CAG triplets in normal, 
heterozygous subjects. This CAG repeat is highly 
polymorphic (Pfeffer et al., 2001). While no 
obvious phenotype was associated with this newly 
discovered polymorphism in the investigated 
cohort, such repeat length variations are critical 
determinants of colon carcinogenesis and 
neurodegenerative disorder when occurring in the 
androgen receptor and huntingtin genes, 
respectively. 
Rett syndrome 
Note 
DLX6 and DLX5 (OMIM #600028) have been 
controversial candidates for neurodevelopmental 
defects progressively afflicting young girls 
suffering of Rett syndrome (OMIM #312750). This 
late onset disorder features fatal motor 
abnormalities, seizures, autism and mental 
retardation. While the genomic sequence of the 
DLX5/DXL6 locus remains unaffected in all 
reported cases, it is a direct target of the 
transcriptional regulator methyl-CpG-binding 
protein 2 (MeCP2), which has been strongly 
associated to this syndrome by linkage analysis 
(Horike et al., 2005). While still debated (Horike et 
al., 2005; Schüle et al., 2007; LaSalle, 2007; 
Miyano et al., 2008), initial MeCP2 deficiency is 
considered as causing defective neurogenesis 
through dysregulated expression of DLX5/DLX6, 
due to altered chromatin state at this target locus 
(Horike et al., 2005; Lilja et al., 2013). Mouse 
mutagenesis has substantiated this hypothesis by 
pinpointing GABA (γ-aminobutyric acid)-releasing 
neurons as a major cellular target expressing Dlx5 
and Dlx6, whose deficiency impairs neurogenesis 
in MeCP2 null mutant (Chao et al., 2010). 
Osteoporosis 
Note 
Mouse mutational studies have demonstrated a role 
for Dlx5 and Dlx6 as a major determinant of 
chondrogenesis and chondrocyte hypertrophy in the 
endochondral skeleton, throughout embryogenesis 
and adulthood (Samee et al., 2007; Samee et al., 
2008; Samee et al., 2009).  
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These observations pave the way for a better 
understanding of human osteoporosis, in particular 
in patients with dysfunctional regulation of bone-
remodeling hormonal levels (Prall et al., 2013). 
Reproductive tract 
Note 
Dlx5 and Dlx6 are involved in the development and 
function of the reproductive tract.  
The dual mouse mutant for Dlx5 and Dlx6 displays 
abnormal urethra formation (Suzuki et al., 2008), 
reduced testicular steroidogenesis with feminization 
(Nishida et al., 2008), and early ovarian follicular 
depletion (Bouhali et al., 2011).  
A human mutation in a genomic region including 
DLX5 and DLX6 has been associated to a case of 
familial premature ovarian failure (Caburet et al., 
2012). 
Teratology 
Note 
With regards to pharmacologically-induced 
teratogenesis, dysregulation of Dlx5/Dlx6 gene 
expression has been demonstrated to be a major 
step during craniofacial embryopathy induced by 
two compounds :  
i) retinoic acid, a vitamin A derivative found in the 
RoAccutane ® drug, which prevents the induction 
of Dlx5/Dlx6 in all animal models investigated 
(Vieux-Rochas et al., 2007; Vieux-Rochas et al., 
2010); this discovery has given strong insight into 
the aetiology of teratologic impact of fetal exposure 
to RoAccutane medication in man.  
Analyses of retinoic acid-induced embryopathy in 
mouse neurulas have demonstrated that retinoic 
acid exposure prevents proper induction of both 
Dlx5 and Dlx6 by endothelin-1 signalling.  
This disruption has been found to be finely tuned 
during a surprisingly short timeframe spanning a 
critical period of neurulation.  
This exposure creates a functional invalidation of 
Dlx5/Dlx6-controlled cranio-facial morphogenesis 
(reviewed in Gitton et al., 2010);  
ii) the food contaminant ochratoxin A, a fungal 
toxin demonstrated to prevent Dlx5 activation in 
exposed mouse embryos, which later develop 
craniofacial malformations (Wei and Sulik, 1993; 
Napoletano et al., 2010).  
Although a causal link between Dlx5, Dlx6 and the 
toxin remains to be functionally demonstrated, this 
observation may account for teratogenesis observed 
in human embryos maternally exposed to the toxin 
(Hope and Hope, 2012; Thrasher et al., 2012). 
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